Profile data is unavailable for this security.
About the company
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a portfolio of precision small molecule product candidates. The Company focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. It advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2022
- Employees58.00
- LocationRapport Therapeutics Inc1325 Boylston Street, Suite 401BOSTON 02215United StatesUSA
- Phone+1 (857) 321-8020
- Fax+1 (302) 655-5049
- Websitehttps://www.rapportrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProKidney Corp | 0.00 | -38.68m | 692.32m | 163.00 | -- | -- | -- | -- | -0.5905 | -0.5905 | 0.00 | -7.73 | 0.00 | -- | -- | 0.00 | -27.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -93.24m | 696.85m | 59.00 | -- | 2.69 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.22m | -109.89m | 701.59m | 201.00 | -- | 1.19 | -- | 34.70 | -2.22 | -2.22 | 0.435 | 11.33 | 0.0416 | -- | -- | 137,544.20 | -22.60 | -32.67 | -23.39 | -34.90 | -- | -- | -543.51 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Adaptive Biotechnologies Corp | 168.77m | -213.47m | 704.92m | 709.00 | -- | 2.92 | -- | 4.18 | -1.47 | -1.47 | 1.16 | 1.64 | 0.2501 | 4.74 | 5.03 | 238,033.80 | -31.65 | -19.69 | -36.63 | -22.06 | 54.77 | 67.18 | -126.55 | -122.27 | 3.84 | -- | 0.3536 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 720.42m | 267.00 | 104.37 | -- | 78.13 | 1.80 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Rapport Therapeutics Inc | -100.00bn | -100.00bn | 740.67m | 58.00 | -- | 2.20 | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Wave Life Sciences Ltd | 110.50m | -73.74m | 740.94m | 266.00 | -- | -- | -- | 6.71 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Annexon Inc | 0.00 | -115.16m | 742.22m | 71.00 | -- | 2.05 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Savara Inc | 0.00 | -75.29m | 763.75m | 37.00 | -- | 6.30 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Replimune Group Inc | 0.00 | -220.01m | 767.25m | 331.00 | -- | 1.80 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 778.82m | 80.00 | -- | 3.43 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Arbutus Biopharma Corp | 10.06m | -77.09m | 781.56m | 73.00 | -- | 6.38 | -- | 77.68 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 787.25m | 107.00 | -- | 2.50 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Stoke Therapeutics Inc | 15.16m | -103.57m | 797.09m | 110.00 | -- | 3.26 | -- | 52.59 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
Data as of Sep 19 2024. Currency figures normalised to Rapport Therapeutics Inc's reporting currency: US Dollar USD
44.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 4.98m | 13.62% |
| Cormorant Asset Management LPas of 30 Jun 2024 | 2.94m | 8.04% |
| Capital Research & Management Co. (International Investors)as of 30 Jun 2024 | 2.60m | 7.12% |
| T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 1.54m | 4.20% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 1.36m | 3.72% |
| AllianceBernstein LPas of 30 Jun 2024 | 1.09m | 2.98% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 748.18k | 2.05% |
| Citadel Advisors LLCas of 30 Jun 2024 | 592.46k | 1.62% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 350.00k | 0.96% |
| Logos Global Management LPas of 30 Jun 2024 | 208.91k | 0.57% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
